



1. Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, Husereau D, Lorenzetti D, Manns B: A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development. *PLoS One* 2014, 9:e90434.
2. Allen N, Pichler F, Wang T, Patel S, Salek S: Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems. *Health Policy* 2013, 113:305-312.
3. Leopold C, Vogler S, Habl C, Mantel-Teeuwisse AK, Espin J: Personalised medicine as a challenge for public pricing and reimbursement authorities - A survey among 27 European countries on the example of trastuzumab. *Health Policy* 2013, 113:313-322.
4. Riedel R, Repschlagler U, Griebenow R, Breitkopf S, Schmidt S, Guhl A: International standards for health economic evaluation with a focus on the German approach. *J Clin Pharm Ther* 2013, 38:277-285.
5. Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C: Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. *ClinicoEconomics and outcomes research : CEOR* 2013, 5:69-85.
6. Cleemput I, Franken M, Koopmanschap M, le Polain M: European drug reimbursement systems' legitimacy: five-country comparison and policy tool. *Int J Technol Assess Health Care* 2012, 28:358-366.
7. Franken M, le Polain M, Cleemput I, Koopmanschap M: Similarities and differences between five European drug reimbursement systems. *Int J Technol Assess Health Care* 2012, 28:349-357.
8. Kleijnen S, George E, Goulden S, d'Andon A, Vitre P, Osinska B, Rdzany R, Thirstrup S, Corbacho B, Nagy BZ, et al: Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. *Value Health* 2012, 15:954-960.
9. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R: Differences in external price referencing in Europe: a descriptive overview. *Health Policy* 2012, 104:50-60.
10. Vogler S: The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries - an overview. *Generics and Biosimilars Initiative Journal* 2012, 1:93-100.
11. Mauskopf J, Walter J, Birt J, Bowman L, Copley-Merriman C, Drummond M: Differences among formulary submission guidelines: implications for health technology assessment. *Int J Technol Assess Health Care* 2011, 27:261-270.
12. Stafinski T, Menon D, Davis C, McCabe C: Role of centralized review processes for making reimbursement decisions on new health technologies in Europe. *ClinicoEconomics and Outcomes Research (Dovepress)* 2011, 3:117-186.
13. Vogler S, Habl C, Bogut M, Voncina L: Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. *Croat Med J* 2011, 52:183-197.
14. Drummond M, Jönsson B, Rutten F, Stargardt T: Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. *The European journal of health economics : HEPAC : health economics in prevention and care* 2011, 12:263-271.
15. Levy AR, Mitton C, Johnston KM, Harrigan B, Briggs AH: International comparison of comparative effectiveness research in five jurisdictions: insights for the US. *Pharmacoeconomics* 2010, 28:813-830.